期刊文献+

9V型肺炎链球菌荚膜多糖降解研究 被引量:1

Research on Degradation of Type 9V Pneumococcal Capsular Polysaccharide
原文传递
导出
摘要 肺炎链球菌荚膜多糖分子质量较大,在制备结合疫苗的过程会有诸多不便,如溶液黏度大、结合过程易过度交联形成凝胶、不易于过滤以及纯化,而荚膜多糖分子片段化是降低其分子质量的有效途径。文章选取了酸水解和超声降解两种方法分别处理9V型肺炎链球菌荚膜多糖。利用不同相对分子质量的葡聚糖在HPLC上的保留时间绘制标准曲线,计算处理后多糖相对分子质量,并通过核磁共振检测结构稳定性,免疫双扩散检测抗原性。实验结果表明,在适宜的条件下,酸水解和超声降解均能有效降低肺炎链球菌荚膜多糖分子质量,减少重复单元,保留重复单元内部结构,保留时间从5.7 min延长到8.25 min,相对分子质量约为580 k。但是酸水解方法破坏了多糖的抗原完整性,而超声降解可以良好保持。 In the process of the preparation of conjugate vaccines, there will be a lot of inconvenience due to the high molecularweight of Streptococcus pneumoniae capsular polysaccharide, for example, the viscosity of the solution is high, the binding process is easy to over cross-link to form a gel and it is difficult to be filtered and purified. The fragmentation of the capsular polysaccharide molecules can effectively reduce its molecular weight. Acid hydrolysis and ultrasonic degradation are selected to reduce the molecular weight of type 9V pneumonia capsular macromolecules polysaccharide. Using different relative molecular weight dextrans and their retention time on HPLC, the standard curve to calculate the relative molecular weight can be drawn. Structural stability can be detected by NMR and antigenicity can be detected by double immunodiffusion. The results showed that the acid hydrolysis and the ultrasonic degradation can effectively decrease the relative molecular weight of pneumonia polysaccharides by reducing duplication units. Retention time increased from 5.7 min to 8.25 min and Mr≈580 ku. Acidic hydrolysis method destroyed the antigenicity of the polysaccharide while ultrasonic degradation could reserve antigenicity.
出处 《药物生物技术》 CAS 2013年第1期49-52,共4页 Pharmaceutical Biotechnology
关键词 肺炎链球菌 荚膜多糖 酸水解 超声 Streptococcus polysaccharide, Capsular polysaccharide, Acid hydrolysis, Ultrasonic
  • 相关文献

参考文献12

  • 1张延龄,张晖,戴科.疫苗学[M].北京:科学出版社,2006.
  • 2Howwark JG, Zola H, Christie GH, et al. Studies on immunological paralysis V. The influence of molecular weight on the immunogenicity, tolerogenicity and antibody-neutralizing activityof type III pneumococcal polysaecharide [ J 1. Immunolo- gy, 1971,21:535.
  • 3Stephen M, Richard LT, Peter JK, et al. Pneumococcal polysac- charide conjugate vaccine[ P]. US5623057,1994-5-20.
  • 4Biemans RL, Garcon NM, Hermand PV, et al. Pneumococcal poly- saccharide conjugate vaccine [ P]. WO 2007/071707, 2006- 12-20.
  • 5Siobhan C, Jean CF, Marie CV. Heterogeneity and homogeneity of an arabinogalactan-protein : Acacia senegal gum [ J ]. Food Hydro- colloids,1987,1 (5-6) :477.
  • 6朱为,荣家康,江元翔,王晓,毕慧,王月红,郑小秋,黄帼英,秦洁.A群和C群脑膜炎球菌荚膜多糖提制工艺研究[J].药物生物技术,2011,18(1):56-60. 被引量:4
  • 7徐张展,邢莹莹,周长林,奚涛.海胆黄多糖SEP酶解及产物免疫活性测定[J].药物生物技术,2009,16(4):342-346. 被引量:5
  • 8Szu SC, Zon G, Schneerson R, et al. Ultrasonic irradiation of bac- terial polysaccharides. Characterization of the depolymerized products and some applications of the process[ J]. Carbohydr Re- search, 1986,152:7.
  • 9Peter JK, Charotte CI, Arpi H, et al. Polysaccharide antigens from streptococcus pneumoniae [ P ]. EP 0497524 A2,1992-1-27.
  • 10李坚斌,李琳,李冰,陈玲,黄国兴.超声降解多糖研究进展[J].食品工业科技,2006,27(9):181-184. 被引量:44

二级参考文献46

共引文献63

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部